← 返回前沿论文

用于多发性骨髓瘤中 BCMA/GPRC5D 共转导 CAR-T 细胞实验室规模制备的可规模化慢病毒工作流程

英文原题:A Scalable Lentiviral Workflow for Laboratory-Scale Generation of BCMA/GPRC5D Co-Transduced CAR-T Cells in Multiple Myeloma.

查看英文原题

A Scalable Lentiviral Workflow for Laboratory-Scale Generation of BCMA/GPRC5D Co-Transduced CAR-T Cells in Multiple Myeloma.

PubMed 2026/06/30(内容时间) Curr Issues Mol Biol Q2 · IF 4.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

高效且可重复的慢病毒载体制备和T细胞转导仍是CAR-T 细胞制造中的重要技术挑战。在本研究中,我们针对靶向BCMA和GPRC5D的慢病毒CAR构建体,优化了HEK293T转染和原代T细胞转导参数。比较了Lipofectamine 3000和TurboFectin 8.0在不同接种密度和试剂与DNA比例下的效果,并通过qPCR和p24 ELISA对载体产量进行定量。与TurboFectin 8.0相比,Lipofectamine 3000始终产生更高的病毒滴度和转导效率,表现为GFP阳性细胞比例更高,抗GPRC5D载体的峰值滴度达到9.65 10 8 copies/mL,抗BCMA载体的峰值滴度达到5.33 10 8 copies/mL。在优化条件下,在测试的TU/mL范围内,BCMA-CAR的转导效率达到43.8% GFP + 细胞,GPRC5D构建体约为13-14% GFP阳性转导细胞。共转导实验获得约62-66% GFP + 细胞,并基于GFP报告基因表达鉴定出可检测的BCMA结合亚群和推测表达GPRC5D-CAR的亚群。免疫表型分析显示CD4/CD8分布相对稳定(约65/35),效应记忆CD8 + 细胞富集,并表达活化相关标志物。

总体而言,这些发现描述了一种优化的慢病毒转染和转导工作流程,可能支持在研究和早期转化环境中进一步开发双靶向BCMA/GPRC5D CAR-T 生产策略。

展开英文摘要原文

Efficient and reproducible lentiviral vector production and T-cell transduction remain important technical challenges in CAR-T (Chimeric Antigen Receptor T-cell) cell manufacturing. In this study, we optimized HEK293T transfection and primary T-cell transduction parameters for lentiviral CAR constructs targeting BCMA (B-cell maturation antigen) and GPRC5D (G-protein coupled receptor family C group 5 member D). Lipofectamine 3000 and TurboFectin 8. 0 were compared across different seeding densities and reagent-to-DNA ratios, with vector yields quantified by qPCR (Quantitative Polymerase Chain Reaction) and p24 ELISA (Enzyme-linked Immunosorbent Assay). Lipofectamine 3000 consistently generated higher viral titers and transduction efficiencies, as reflected by a greater proportion of GFP-positive (Green Fluorescent Protein) cells than TurboFectin 8. 0, reaching peak titers of 9.

65 10 8 copies/mL for the anti-GPRC5D and 5. 33 10 8 copies/mL for the anti-BCMA vectors. Under optimized conditions, transduction efficiencies reached 43. 8% GFP + cells for BCMA-CAR and approximately 13-14% GFP-positive transduced cells for the GPRC5D construct within the tested TU/mL range. Co-transduction experiments yielded approximately 62-66% GFP + cells with detectable BCMA-binding and presumptive GPRC5D-CAR-expressing subpopulations identified based on GFP reporter expression.

Immunophenotypic analysis demonstrated a relatively stable CD4/CD8 distribution (~65/35), enrichment of effector memory CD8 + cells, and expression of activation-associated markers. Collectively, these findings describe an optimized lentiviral transfection and transduction workflow that may support the further development of dual-targeting BCMA/GPRC5D CAR-T manufacturing strategies in research and early translational settings.

论文信息

作者
Nowak E、Morawiec E、Pudełko A、Polak A、Broncel M、Matczyńska D、Zamojski D、Czerwinski M
单位
Gyncentrum Sp. z o.o. Medical Diagnostic Laboratory, Genetics and Molecular Biology in Sosnowiec, 40-851 Katowice, Poland.Poland
期刊
Current issues in molecular biology2026 Jun 30
原文标识
PubMed 42510920 · DOI 10.3390/cimb48070679